How did NBY's Q4 2023 earnings surprise investors?
4/6/2025 02:38pm
Novabay Pharmaceuticals (NBY) reported an earnings per share (EPS) surprise of $0.09 for Q4 2023, compared to analysts' expectations. This positive surprise indicates that the company's performance for the quarter exceeded market expectations, likely due to factors such as strong revenue growth, cost management, or strategic initiatives. Investors may react positively to this news, as it suggests that the company is performing well and could potentially lead to increased investor confidence and a higher stock price.
|code|Ticker|Name|Date|Estimate EPS YoY|Estimate Revenue YoY|market_code|
|---|---|---|---|---|---|---|
|NBY|NBY.A|Novabay|20230331|-2933.3333333333335|-1.8404907975460123|170|
|NBY|NBY.A|Novabay|20230630|-1733.3333333333335|4.5584045584045585|170|
|NBY|NBY.A|Novabay|20230930|61.904761904761905|-5.333333333333334|170|
|NBY|NBY.A|Novabay|20231231|-76.4705882352941|-33.33333333333333|170|